29.07.2011 • NewsH1 2011Lindesales and profits

Linde H1 Earnings Up

Linde Group's six-month earnings attributable to Linde AG shareholders after adjusting for non-controlling interests advanced to €566 million from €445 million last year. Earnings after tax rose 23.8% to €598 million from €483 million a year ago.

In the first half of 2011, group sales improved 11% to €6.77 billion from €6.10 billion in the comparable period a year ago. After adjusting for exchange rate effects, the increase in sales was 10.3%.

Earnings per share grew by 26.2% to €3.32 from €2.63 a year earlier. On an adjusted basis, after adjusting for the effects of the purchase price allocation from the 2006 BOC acquisition, earnings per share stood at €3.79 compared with €3.15 in 2010.

The company confirmed its outlook and expects to achieve growth in group sales and group operating profit in the 2011 financial year compared with the prior year.

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.